Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101013 | 0.84 | CARM1 (0.39) | ALDH1A1MAPK1 | |
| SCHEMBL11618482 | 0.68 | MAPT (0.38) | MAPTHPGDSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL15484875 | 0.65 | — | — | |
| SCHEMBL10851307 | 0.65 | MAOA (0.38) | ALDH1A1MAPK1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL4964623 | 0.65 | SLC22A12 (0.44) | ALDH1A1MAPTHPGDSMN1; SMN2MGLL | |
| SCHEMBL11066307 | 0.65 | SIGMAR1 (0.50) | ALDH1A1MAPTHSD17B10OPRM1 | |
| SCHEMBL4967515 | 0.63 | SIRT1 (0.39) | ALDH1A1MAPK1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL10963262 | 0.63 | MEN1 (0.35) | ALDH1A1MAPK1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL11211405 | 0.62 | CRBN (0.38) | ALDH1A1MAPK1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL774771 | 0.60 | MAPT (0.39) | ALDH1A1MAPK1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010029297-A1 | Chemical synthesis of spirocyclic piperidines by double ring-closing metathesis | MERCK SHARP & DOHME LTD. (GB) | 2001-10-11 | — | — | US | claimed |
| US-10329297-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
| US-9771370-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2017-09-26 | — | — | US | disclosed |
| US-9771370-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2017-09-26 | — | — | US | disclosed |
| CN-107074859-A | Indoleamine 2, the diaza and three aza-tricycle compounds of the cyclohexyl-ethyl substitution of 3 dioxygenases (IDO) antagonist are used as treating cancer | 默克专利有限公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-3189054-A1 | CYCLOHEXYL-ETHYL SUBSTITUTED DIAZA- AND TRIAZA-TRICYCLIC COMPOUNDS AS INDOLE-AMINE-2,3-DIOXYGENASE (IDO) ANTAGONISTS FOR THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2303270-B1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-05-17 | — | — | EP | disclosed |
| WO-1998024442-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEXUAL DYSFUNCTION | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024444-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SUBSTANCE USE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024445-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SCHIZOPHRENIC DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024443-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING BIPOLAR DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024447-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024439-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEVERE ANXIETY DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024438-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024441-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS WITH ANXIETY | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998001450-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1998-01-15 | — | — | WO | disclosed |
| WO-1997049710-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | IDO1, IDO2, INMT | ALDH1A1 935/4885MAPK1 2897/4885MAPT 1582/4885 |
| US-20010029297-A1 | Chemical synthesis of spirocyclic piperidines by double ring-closing metathesis | CTPS1, DHPS, CTPS2 | ALDH1A1 236/4885MAPK1 1027/4885MAPT 3889/4885 |
| US-10329297-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | IDO1, IDO2, INMT | ALDH1A1 935/4885MAPK1 2897/4885MAPT 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.